Madrigal Pharmaceuticals, Inc. MDGL Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total non-current liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total non-current liabilities of $345.61M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total non-current liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total non-current liabilities increased by 191.0% year-over-year, from $118.76M to $345.61M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total non-current liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total non-current liabilities has grown at a 274.9% compound annual growth rate (CAGR), from $468K to $346.61M.
- What does total non-current liabilities mean?
- Total debts and obligations due after more than one year.
- How do you interpret total non-current liabilities?
- An increase indicates a higher long-term financial burden, which requires future cash flow to service.
- How does total non-current liabilities compare across companies?
- Used to evaluate the long-term debt-to-equity profile compared to industry peers.